• BioMarin Pharmaceutical Inc., of Novato, Calif., said it started a Phase I study in healthy volunteers for BMN-111, an analogue of C-type natriuretic peptide in development for achondroplasia. The trial is a two-part study designed to test single and multiple subcutaneous doses of the drug in up to 74 subjects. Data are expected in the third quarter of this year.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter